Lilly Approves $15 Billion in Share Buybacks, Raises Dividend

Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.

The company also raised its quarterly dividend 15%, according to a statement Monday. The shares rose as much as 1.3% in late trading after the US markets closed.